Generation of an integration-free induced pluripotent stem cell line (FDEENTi003-A) from a patient with pathological myopia

Xinyue Bai\textsuperscript{a,b,c}, Xian-Jie Yang\textsuperscript{d}, Ling Chen\textsuperscript{a,b,c,*}

\textsuperscript{a}Department of Ophthalmology & Vision Science, Eye & ENT Hospital, Shanghai Medical School, Fudan University, Shanghai, China

\textsuperscript{b}Key NHC Key Laboratory of Myopia (Fudan University), Laboratory of Myopia, Chinese Academy of Medical Sciences, China

\textsuperscript{c}Shanghai Key Laboratory of Visual Impairment and Restoration, Eye & ENT Hospital, Shanghai Medical School, Fudan University, Shanghai, China

\textsuperscript{d}Jules Stein Eye Institute, University of California Los Angeles, California, USA

Abstract

Pathological myopia (PM) is a major cause of irreversible vision impairment worldwide. We have successfully reprogrammed the peripheral blood mononuclear cells (PBMCs) from a PM patient to induced pluripotent stem cells and characterized their pluripotency and genetic stability, as well as the potential to differentiate to retinal pigment epithelium (RPE). This line may serve as a useful tool to explore the pathogenesis of PM.

Resource Utility

Pathological myopia (PM) is a major cause of irreversible vision impairment worldwide. A lack of elaborated etiology and suitable animal models makes it an incurable disease. The FDEENTi003-A iPSC line may serve as a useful tool to explore the pathogenesis of PM.

Resource Details

Pathological myopia (PM) is a major cause of irreversible vision impairment and blindness worldwide, especially in Asia. It refers to highly myopic eyes with characteristic chorioretinal atrophy, which often leads to progressive and irreversible vision loss (Ohno-Matsui et al., 2018). Pathogenesis of PM is complex and still unclear, partly due to the limited access to patients’ atrophic retina tissues and a lack of animal models to recapitulate the disease phenotypes.

To provide a source of patient retinal tissue of PM for study, we generated a patient-derived PM-specific induced pluripotent stem cell (iPSC) line and differentiated it into...
retinal pigment epithelium (RPE), one of the ten layers of retina. A 55-year-old female patient presented with high myopia accompanied by characteristic chorioretinal atrophy in both eyes. Peripheral blood was collected and freshly isolated for mononuclear cells. The cells were reprogrammed by Sendai viral vectors expressing OCT4, SOX2, KLF4 and C-MYC (Ban et al., 2011). The established FDEENTi003-A line exhibited a typical morphology of human embryonic stem cell (hESC) colonies (Fig. 1A, Table 1) and was positive for alkaline phosphatase staining (Fig. 1B). The expression of major pluripotent markers was examined by immunocytochemical staining using antibodies against human OCT4, SOX2, NANOG (Fig. 1G). Quantitative polymerase chain reaction (qPCR) showed that OCT4, SOX2 and NANOG mRNA was expressed at similar levels between FDEENTi003-A iPSC and hESC and was hardly expressed /absent in the parental PBMCs (Fig. 1C). The FDEENTi003-A line showed a normal diploid 46, XX karyotype (at passage 10) (Fig. 1D) and was genetically authenticated with the patient’s peripheral blood cells by short tandem repeat (STR) analysis. SeV genome and transgenes were absent at passage 11 as confirmed by RT-PCR (Fig. 1E). PCR testing demonstrated the absence of mycoplasma contamination (Fig. 1F). Trilineage differentiation potential was detected in vitro and confirmed by the expression of ectoderm (PAX6), mesoderm (MESP1), and endoderm (FOXA2) markers (Fig. 1H). Furthermore, the potential for differentiation into retina was confirmed by directed differentiation into RPE, one of the ten layers of human retina. Patient-derived iPSC-RPE exhibited a typical polygonal morphology similar to that of human RPE cells, pigmented, and expressed major RPE markers (ZO-1, BEST1, MITF) (Fig. 1).

Materials and methods

Cell culture and reprogramming

PBMCs were isolated from the whole blood sample using Histopaque®-1077 (Sigma-Aldrich) and cultured in StemSpan SFEMIImedium (Stem Cell Technologies) supplemented with 100 ng/mL SCF, 100 ng/mL FLT-3 L, 20 ng/mL IL-3 and 20 ng/mL IL-6 cytokines (Peprotech). Five days later, the cells were collected and transduced with CytoTune®-iPS 2.0 Sendai reprogramming vectors (Thermo Fisher) following the manufacturer’s instruction. The transduced cells were plated onto irradiated mouse embryonic fibroblasts (MEFs) and maintained in mTeSR™1 medium (Stem Cell Technologies) which was changed every other day. Around day 16 post-transduction, ESC-like colonies appeared and were manually picked on day 20 post-transduction. The established iPSCs were cultured on Matrigel (Corning)-coated plates in mTeSR™1 medium at 37 °C with 5% CO₂ and routinely passaged at 1:3 ratio using dispase (Stem Cell Technologies) every 4–6 days. The iPSCs were frozen in CryoStor® CS10 freezing medium and thawed with 10 μM Y-27632 (Stem Cell Technologies). hESC (H7 [Wi Cell Research Institute, Madison, WI, USA]) was cultured in parallel with FDEENTi003-A.

Alkaline phosphatase (AP) staining

Cells were fixed in 4% PFA for 1–2 min and stained for alkaline phosphatase according to Alkaline Phosphatase Detection Kit protocol (Innovative Cellular Therapeutics, China).
**Immunocytochemistry**

Cells were fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.2% Triton X-100 for 15 min, and blocked in 4% bovine serum albumin for 30 min at room temperature. Afterwards, they were incubated with primary antibodies at 4 °C overnight and visualized with secondary antibodies for 1 h at room temperature. Both primary and secondary antibodies were diluted in PBS with 1% bovine serum albumin. Nuclei were stained with Hoechst (Thermo Fisher) for 5 min at room temperature. Images were taken by inverted fluorescence microscope (Leica Microsystems, Germany). Antibodies used are listed in Table 2.

**IPSC differentiation**

For trilineage differentiation, iPSCs were cultured to approximately 70% confluency. Then they were harvested using ACCUTASE™ (Stem Cell Technologies) and plated for trilineage differentiation according to the STEMdiff™ Trilineage Differentiation Kit protocol (Stem Cell Technologies). Five or seven days later, the cells were fixed in 4% paraformaldehyde for assessing lineage specific markers by immunocytochemistry.

For directed differentiation into RPE cells, we followed a previously published protocol (Foltz and Clegg, 2017). After differentiation and maturation for 3 months, iPSC-RPE were tested for morphology and pigmentation and immunostained for RPE markers.

**RT-PCR and qPCR analysis**

Total RNA was extracted using TRIzol® Reagent (Thermo Fisher). 500 ng RNA was reverse transcribed into cDNA using PrimeScript™ RT Master Mix (Takara). RT-PCR was performed on the S1000 Thermal Cycler (BIO-RAD) using EasyTaq® PCR SuperMix (Transgen, China) and analyzed by agarose gel electrophoresis. The cycle parameters were as follows: 95 °C for 5 min followed by 35 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s. qPCR was conducted on ViiA™ 7 Real-Time PCR System (Applied Biosystems) and analyzed using the ΔΔCT method. Primers used are listed in Table 2.

**Karyotyping**

FDEENTi003-A cells in the logarithmic phase at passage 10 were treated with colchicine for 4 h and then dissociated into single cells using Accutase(Stem Cell Technologies). The standard G-banding karyotyping was performed by KingMed Diagnostics, Shanghai and 20 metaphase spreads were counted.

**Short tandem repeat (STR) analysis**

gDNA was isolated using a commercial kit from CORNING (AP-EMN-BL-GDNA-250G). STR analysis was performed on the PBMCs and established iPSCs with detection of 20 loci (D3S1358, D8S1179, D19S433, AMEL, VWA, D21S11, TH01, D5S818, D7S820, D16S539, D13S17, D12S391, CSF1PO, D2S1338, TPOX, FGA, PENTAE, PENTAD, D18S51, D6S1043, D1S1656) by Shanghai Biowing Applied Biotechnology Co, LTD, China.
Mycoplasma test

The absence of mycoplasma was confirmed by EZ-PCR Mycoplasma Test Kit (Biological Industries, BI) following the manufacturer’s instruction.

Acknowledgements

This study was funded by the National Natural Science Foundation of China (No.81870660 and No.81371042), Shanghai Science and Technology Foundation (18ZR1405900) and Shanghai Hospital Development Center (SHDC12016116) to L. Chen, and in part supported by NIH grants R01EY026319 to X-J Yang, and unrestricted grant from the Research to Prevent Foundation at University of California Los Angeles. The samples used for the analyses described in this manuscript were obtained from the EENT Biobank. We would like to thank all the participants and the staffs (Haihong Zhou and Wentao Wang) for their valuable contribution to this research.

References

Ban H, Nishishita N, Fusaki N, Tabata T, Saeki K, Shikamura M, Takada N, Inoue M, Hasegawa M, Kawamata S, Nishikawa S, 2011. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad. Sci. U. S. A. 108, 14234–14239. [PubMed: 21821793]

Foltz LP, Clegg DO Rapid, 2017. Directed differentiation of retinal pigment epithelial cells from human embryonic or induced pluripotent stem cells. J. Vis. Exp. 128, e56274.

Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM, 2018. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog. Retin. Eye Res. 63, 92–106. [PubMed: 29111299]
Fig. 1.
Characterization of iPSC line FDEENTi003-A.
### Table 1

Characterization and validation.

| Classification        | Test                                      | Result                                                                 | Data                        |
|-----------------------|-------------------------------------------|------------------------------------------------------------------------|-----------------------------|
| Morphology            | Photography                               | Normal                                                                 | Fig. 1 panel A              |
|                       | Qualitative analysis: Immunocytochemistry | Positive for pluripotency markers: OCT4, SOX2, NANOG                    | Fig. 1 panel G              |
|                       | Quantitative analysis: RT-qPCR             | Positive for pluripotency markers: OCT4, SOX2, NANOG                    | Fig. 1 panel C              |
| Phenotype             | Karyotype (G-banding) and resolution       | 46XX, Resolution 400                                                   | Fig. 1 panel D              |
|                       | Microsatellite PCR (mPCR) OR STR analysis | N/A                                                                    | Available with authors.     |
| Identity              |                                            | 21 loci tested, 100% matched                                          |                             |
| Genotype              | Sequencing                                | Not performed                                                          | N/A                         |
|                       | Southern Blot OR WGS                      | Not performed                                                          | N/A                         |
|                       | Mycoplasma                                | Mycoplasma testing by RT-PCR: Negative                                  | Fig. 1 panel F              |
| Microbiology and virology | Direct differentiation                   | Proof of three germ layers formation: ectoderm (PAX6), mesoderm (MESP1) and endoderm (FOXA2)| Fig. 1 panel H              |
| Differentiation potential | HIV 1 + 2 Hepatitis B, Hepatitis C      | Not performed                                                          | N/A                         |
|                       | Blood group genotyping                    | Not performed                                                          | N/A                         |
|                       | HLA tissue typing                         | Not performed                                                          | N/A                         |

Stem Cell Res. Author manuscript; available in PMC 2020 March 17.
Table 2

Reagents details.

Antibodies used for immunocytochemistry/flow-citometry

| Antibody                  | Dilution | Company Cat # and RRID          |
|---------------------------|----------|---------------------------------|
| Pluripotency Markers      |          |                                 |
| Rabbit anti-OCT4          | 1:200    | Abcam Cat# ab181557, RRID: AB_2687916 |
| Rabbit anti-SOX2          | 1:200    | Abcam Cat# ab92494, RRID: AB_10585428 |
| Rabbit anti-NANOG         | 1:100    | Abcam Cat# ab21624, RRID: AB_446437 |
| Differentiation Markers   |          |                                 |
| Rabbit anti-PAX6          | 1:200    | Abcam Cat# ab195045, RRID: AB_2750924 |
| Mouse anti-MESP1          | 1:200    | Abcam Cat# ab77013, RRID: AB_1566419 |
| Rabbit anti-FOXA2         | 1:200    | Abcam Cat# ab108422, RRID: AB_11157157 |
| RPE Markers               |          |                                 |
| Rabbit anti-ZO-1          | 1:100    | Thermo Fisher Scientific Cat# 402200, RRID: AB_2533456 |
| Mouse anti-BEST1          | 1:100    | Abcam Cat# ab2182, RRID: AB_302880 |
| Mouse anti-MITF           | 1:100    | Abcam Cat# ab3201, RRID: AB_303601 |
| Secondary antibodies      |          |                                 |
| AlexaFlour488 goat anti-mouse IgG | 1:1000 | Thermo Fisher Scientific Cat# A-11001, RRID: AB_2534069 |
| Secondary antibodies      |          |                                 |
| AlexaFlour488 goat anti-rabbit IgG | 1:1000 | Thermo Fisher Scientific Cat# A-11008, RRID: AB_143165 |
| Secondary antibodies      |          |                                 |
| AlexaFlour555 goat anti-mouse IgG | 1:1000 | Thermo Fisher Scientific Cat# A-21422, RRID: AB_2535844 |

Primers

| Target                               | Forward/Reverse primer (5’→3’)                                |
|--------------------------------------|---------------------------------------------------------------|
| Sendai viral vector (RT-PCR)         | GGATCACTAGGTGATCGAGGATCGAGG/GGTTTAAAGAGTAGATGATGATG          |
| KOS/528 bp                           | ATGCACCGCTAGCGTAGGC/ACCTTGACAATGATGATG                      |
| KLF4/410 bp                          | TTCTCGATGGCGGAGAGGCGC/AAACTGATCGAAGGATGTCCTAA               |
| C-MYC/532 bp                         | TAATCGACTAGCGTGTGTGGGCG/CTCCACATAGCTCGAGATGATG               |
| Pluripotency Markers (qPCR)          | GGATCACTAGGTGATCGAGGATCGAGG/GGTTTAAAGAGTAGATGATG          |
| OCT4/169 bp                          | ATGCACCGCTAGCGTAGGC/ACCTTGACAATGATGATG                      |
| SOX2/171 bp                          | TTCTCGATGGCGGAGAGGCGC/AAACTGATCGAAGGATGTCCTAA               |
| NANOG/179 bp                         | TAATCGACTAGCGTGTGTGGGCG/CTCCACATAGCTCGAGATGATG               |
| House-Keeping Genes (qPCR)           | GGATCACTAGGTGATCGAGGATCGAGG/GGTTTAAAGAGTAGATGATG          |
| β-ACTIN/110 bp                       | ATGCACCGCTAGCGTAGGC/ACCTTGACAATGATGATG                      |
## Resource Table

| Unique stem cell line identifier | FDEENTi003-A |
|---------------------------------|--------------|
| Alternative name(s) of stem cell line | ZSY-IPS |
| Institution | Eye & ENT Hospital, Shanghai Medical School, Fudan University, Shanghai, China |
| Contact information of distributor | Xinyue Bai, xinyue_bai@126.com |
| | Ling Chen, linglingchen98@hotmail.com |
| Type of cell line | iPSC |
| Origin | Human |
| Additional origin info | Age: 55 |
| | Sex: female |
| | Ethnicity: Han Chinese |
| Cell Source | Peripheral blood mononuclear cells (PBMCs) |
| Clonality | Clonal |
| Method of reprogramming | Transgene free, Sendai viral vectors |
| Genetic Modification | NO |
| Type of Modification | N/A |
| Associated disease | Pathological myopia |
| Gene/locus | N/A |
| Method of modification | N/A |
| Name of transgene or resistance | N/A |
| Inducible/constitutive system | N/A |
| Date archived/stock date | 1st October 2018 |
| Cell line repository/bank | [https://hpscreg.eu/cell-line/FDEENTi003-A](https://hpscreg.eu/cell-line/FDEENTi003-A) |
| Ethical approval | This study was approved by the ethics committee of Fudan University affiliated Eye & ENT Hospital (KJ2011-04). |